Pluri (PLUR) Non-Current Deferred Tax Liability (2025)

Pluri (PLUR) reported Non-Current Deferred Tax Liability of $400000.0 for Q4 2025, down 1.72% quarter-over-quarter from $407000.0 in Q3 2025.

Pluri (PLUR) Non-Current Deferred Tax Liability (2025) Analysis & Trends

Pluri (PLUR) has 1 years of Non-Current Deferred Tax Liability data on file, last reported at $400000.0 in Q4 2025.

Non-Current Deferred Tax Liability for Q4 2025 came in at $400000.0, changed N/A year-over-year; the trailing twelve-month figure through Dec 2025 was $400000.0 (changed N/A YoY), and the FY2025 annual result was $415000.0, changed N/A from the prior year.
Non-Current Deferred Tax Liability slipped to $400000.0 in Q4 2025 per PLUR's latest filing, from $407000.0 in the prior quarter.
Over five years, Non-Current Deferred Tax Liability peaked at $415000.0 in Q2 2025 and troughed at $400000.0 in Q4 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Alterity Therapeutics	719,706.53 Bn	719,706.50 Bn	-
2	Belite Bio	55,800.00 Bn	55,800.00 Bn	-
3	Quantum Biopharma	18,182.30 Bn	18,182.29 Bn	-
4	Legend Biotech	3,154.00 Bn	3,153.71 Bn	242.10 Mn
5	Akari Therapeutics	1,844.30 Bn	1,844.29 Bn	-
6	Evaxion A	1,567.96 Bn	1,567.94 Bn	-
7	Psyence Biomedical	251.43 Bn	251.42 Bn	-
8	Vertex Pharmaceuticals	112.56 Bn	105.31 Bn	2.59 Bn
9	Abivax	94.37 Bn	94.37 Bn	-
10	Pluri	21.39 Mn	21.87 Mn	86,000.00

Download Data